Nurix Therapeutics (NRIX) Short-term Investments (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Short-term Investments for 8 consecutive years, with $375.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Short-term Investments fell 6.39% year-over-year to $375.8 million; the TTM figure through May 2026 stood at $375.8 million (down 6.39% YoY), while the FY2025 annual figure was $346.0 million, down 30.75% from the prior year.
• Short-term Investments eased to $375.8 million in Q2 2026 per NRIX's latest filing, from $469.5 million in the prior quarter.
• Across five years, Short-term Investments topped out at $499.6 million in Q4 2024 and bottomed at $183.2 million in Q1 2022.
• Historically, Short-term Investments has averaged $315.7 million across 5 years, with a median of $311.6 million in 2022.
• On a YoY basis, Short-term Investments climbed as much as 143.98% in 2025 and fell as far as 30.75% in 2025.
• Nurix Therapeutics' Short-term Investments stood at $244.7 million in 2022, then slipped by 4.65% to $233.3 million in 2023, then jumped by 114.16% to $499.6 million in 2024, then sank by 30.75% to $346.0 million in 2025, then grew by 8.63% to $375.8 million in 2026.
• Business Quant data shows NRIX's Short-term Investments at $375.8 million in Q2 2026, $469.5 million in Q1 2026, and $346.0 million in Q4 2025.